CN114931591A - Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases - Google Patents
Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases Download PDFInfo
- Publication number
- CN114931591A CN114931591A CN202210461930.1A CN202210461930A CN114931591A CN 114931591 A CN114931591 A CN 114931591A CN 202210461930 A CN202210461930 A CN 202210461930A CN 114931591 A CN114931591 A CN 114931591A
- Authority
- CN
- China
- Prior art keywords
- leaf extract
- hibiscus
- cotton rose
- extract
- nematodes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 230
- 244000048199 Hibiscus mutabilis Species 0.000 title claims abstract description 228
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 44
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 235000003973 Hibiscus mutabilis Nutrition 0.000 title claims description 122
- 235000005206 Hibiscus Nutrition 0.000 title 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 title 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000469 ethanolic extract Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000004900 autophagic degradation Effects 0.000 abstract description 61
- 238000011282 treatment Methods 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 35
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 24
- 230000006698 induction Effects 0.000 abstract description 16
- 238000010171 animal model Methods 0.000 abstract description 6
- 241000244206 Nematoda Species 0.000 description 142
- 210000004027 cell Anatomy 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 54
- 208000024827 Alzheimer disease Diseases 0.000 description 30
- 102000013498 tau Proteins Human genes 0.000 description 28
- 108010026424 tau Proteins Proteins 0.000 description 25
- 230000000324 neuroprotective effect Effects 0.000 description 24
- 230000009261 transgenic effect Effects 0.000 description 23
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 20
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 20
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 20
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 235000013305 food Nutrition 0.000 description 16
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 15
- 230000001976 improved effect Effects 0.000 description 15
- 206010033799 Paralysis Diseases 0.000 description 14
- 230000002776 aggregation Effects 0.000 description 14
- 238000004220 aggregation Methods 0.000 description 14
- 208000023105 Huntington disease Diseases 0.000 description 13
- 102000003802 alpha-Synuclein Human genes 0.000 description 13
- 108090000185 alpha-Synuclein Proteins 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 230000008447 perception Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108091030071 RNAI Proteins 0.000 description 10
- 230000015556 catabolic process Effects 0.000 description 10
- 238000006731 degradation reaction Methods 0.000 description 10
- 230000009368 gene silencing by RNA Effects 0.000 description 10
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 102100023408 KH domain-containing, RNA-binding, signal transduction-associated protein 1 Human genes 0.000 description 9
- 101800001821 Precursor of protein E3/E2 Proteins 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 230000032683 aging Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 101800002664 p62 Proteins 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 8
- 208000010877 cognitive disease Diseases 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 238000012347 Morris Water Maze Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 7
- 230000001149 cognitive effect Effects 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 230000001360 synchronised effect Effects 0.000 description 7
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 6
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 206010027175 memory impairment Diseases 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 4
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 108010087230 Sincalide Proteins 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 239000012822 autophagy inhibitor Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000034958 pharyngeal pumping Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 240000005959 Abelmoschus manihot Species 0.000 description 3
- 235000001075 Abelmoschus manihot Nutrition 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101100071615 Caenorhabditis elegans hsp-6 gene Proteins 0.000 description 3
- 101100316118 Caenorhabditis elegans unc-51 gene Proteins 0.000 description 3
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 3
- 101100190557 Caenorhabditis elegans vps-34 gene Proteins 0.000 description 3
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 101800001718 Amyloid-beta protein Proteins 0.000 description 2
- 208000031873 Animal Disease Models Diseases 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101100325855 Caenorhabditis elegans bec-1 gene Proteins 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 238000010867 Hoechst staining Methods 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 238000010826 Nissl staining Methods 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- 230000006933 amyloid-beta aggregation Effects 0.000 description 2
- 238000011558 animal model by disease Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000009193 crawling Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 238000010174 APPSwe Methods 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010032769 Autophagy-Related Protein 8 Family Proteins 0.000 description 1
- 102000007353 Autophagy-Related Protein 8 Family Human genes 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101100273751 Caenorhabditis elegans cdc-42 gene Proteins 0.000 description 1
- 101100241173 Caenorhabditis elegans dat-1 gene Proteins 0.000 description 1
- 101100393846 Caenorhabditis elegans gst-4 gene Proteins 0.000 description 1
- 101100292356 Caenorhabditis elegans mtl-2 gene Proteins 0.000 description 1
- 101100203566 Caenorhabditis elegans sod-3 gene Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- MUVGVMUWMAGNSY-YCBKVTMHSA-N Corynoxeine Natural products O=C(OC)/C(=C\OC)/[C@@H]1[C@@H](C=C)CN2[C@H]([C@@]3(C(=O)Nc4c3cccc4)CC2)C1 MUVGVMUWMAGNSY-YCBKVTMHSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100449774 Musca domestica Gst4 gene Proteins 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- -1 PS1M146V knock-in Proteins 0.000 description 1
- 101150035190 PSEN1 gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710170789 Protein bax Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100533820 Rattus norvegicus Sod3 gene Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010797 grey water Substances 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MUVGVMUWMAGNSY-KAXDATADSA-N methyl (e)-2-[(3r,6'r,7's,8'as)-6'-ethenyl-2-oxospiro[1h-indole-3,1'-3,5,6,7,8,8a-hexahydro-2h-indolizine]-7'-yl]-3-methoxyprop-2-enoate Chemical compound O=C1NC2=CC=CC=C2[C@]21CCN1[C@H]2C[C@H](\C(=C/OC)C(=O)OC)[C@@H](C=C)C1 MUVGVMUWMAGNSY-KAXDATADSA-N 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004723 neuronal vulnerability Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000002267 nissl body Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000001184 pharyngeal muscle Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000001848 seam cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000007788 spatial learning performance Effects 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UGODCLHJOJPPHP-AZGWGOJFSA-J tetralithium;[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-2-[[oxido(sulfonatooxy)phosphoryl]oxymethyl]oxolan-3-yl] phosphate;hydrate Chemical compound [Li+].[Li+].[Li+].[Li+].O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OS([O-])(=O)=O)[C@@H](OP([O-])([O-])=O)[C@H]1O UGODCLHJOJPPHP-AZGWGOJFSA-J 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 101150114748 unc-119 gene Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Psychology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of medicinal chemistry, in particular to application of a cotton rose hibiscus leaf extract in a medicament for treating neurodegenerative diseases. The cotton rose hibiscus leaf extract has obvious treatment effect on various caenorhabditis elegans, cells and neurodegenerative diseases of animal models through autophagy induction.
Description
Technical Field
The invention relates to the field of medicinal chemistry, in particular to application of a cotton rose hibiscus leaf extract in a medicament for treating neurodegenerative diseases.
Background
Neurodegenerative Diseases (NDs) are a clinical aging-related disease, and with the accelerated aging of the global population, the morbidity and mortality of neurodegenerative diseases are gradually increased worldwide, which brings huge economic and health burden to the society and individual families. Unfortunately, despite decades of intensive research, there is currently no effective strategy for treating or preventing NDs, and existing treatments only alleviate the symptoms of these diseases or delay the progression of the diseases. Therefore, the search for new effective methods for preventing or treating NDs is urgent.
At present, much research has been carried out on the pathophysiology of NDs, but the understanding of their pathogenesis is still not comprehensive or clear enough. Nevertheless, at the genetic, molecular or cellular level, certain substances or events have been found to recur in patients with NDs, such as protein misfolding and aggregation, neuroinflammation, increased neuronal vulnerability, mitochondrial dysfunction, oxidative stress and iron accumulation. Since familial NDs are often associated with genetic mutations, these mutated genes significantly enhance the aggregation propensity of disease-associated proteins, such as Amyloid Precursor Protein (APP) and Tau protein in Alzheimer's Disease (AD), alpha-synuclein (alpha-synuclein) in PD and hungtintin protein in Huntington's Disease (HD).
More and more studies have shown that protein misfolding and aggregation may play a crucial role in the pathogenesis of NDs. Although there is no apparent similarity in sequence, size, structure, expression level or function between different such classes of NDs-associated aggregated proteins, the processes of misfolding and aggregation of these proteins are very similar.
It has been found that in the brain of NDs, all disease-related proteins misfold from their original state to form intermolecular β -sheet structures ranging from small oligomers to large fibrillar aggregates. Furthermore, a recent breakthrough research finding suggests that misfolded proteins may transfer abnormal pathological proteins between cells and tissues in a prion-like manner via a self-transfer pathway. This finding is important to understand the mechanism of initiation and progression of NDs and suggests that misfolding and transport aggregation of certain proteins are the underlying cause of a particular disease. Thus, targeted clearance of misfolded proteins and reduction of their aggregation appears to be a promising strategy for the treatment of various NDs.
It is well known that the autophagy-lysosomal pathway (ALP) and the ubiquitin-protein system (UPS) are two major proteolytic systems in cells, which play a key role in clearing misfolded proteins, aggregates and damaged organelles. Some recent research results show that the ubiquitin protease system has limited degradation ability to aggregate misfolded proteins, and more importantly depends on autophagy-lysosome pathway to degrade the corresponding protein. Therefore, more and more research is tending to find strategies to treat NDs that can target activation of autophagy.
At present, several compounds capable of enhancing autophagy activity have been discovered and identified, such as curcumin, corynoxeine B, chlorogenic acid, quercetin, resveratrol, etc., which have been shown to exhibit significant neuroprotective effects in cell systems or animal disease models. However, autophagy inducers are still in the initial phase for the treatment of NDs, and most clinical trials of inducers end up with a failure. Although they show promising results in vitro (cellular systems) and in vivo (animal disease models), the majority of autophagy inducing agents are excluded from clinical trials due to toxicity and excessive side effects, limited or ineffective action. Therefore, the development of new safe and effective drugs for treating NDs remains a great challenge, and the strategy for screening novel autophagy inducers must be optimized to improve the possibility of clinical trials and applications.
In recent years, natural products have received increasing attention in the prevention or treatment of NDs. Traditional Chinese Medicine (TCM) provides new possibility for developing potential effective anti-NDs drug pairs due to the advantages of long-term clinical verification, multiple components, multiple targets, high safety, low toxicity and side effects and the like.
Disclosure of Invention
The invention aims to: aiming at the problems of excessive toxicity and side effect, poor treatment effect and even ineffectiveness of an autophagy inducer in the prior art, the application of the cotton rose hibiscus leaf extract in the medicines for treating neurodegenerative diseases is provided.
In order to achieve the purpose, the invention adopts the technical scheme that:
the application of the cotton rose hibiscus leaf extract in preparing the medicines for treating the neurodegenerative diseases is disclosed, wherein the cotton rose hibiscus leaf extract is a cotton rose hibiscus leaf ethanol extract.
The inventor verifies through experiments that the cotton rose hibiscus leaf extract can promote the formation of GFP-LC3 points in GFP-RFP-LC 3U 87 cells, increase the expression of LC3B in PC-12 cells and 3 × Tg-AD mice and reduce the expression of autophagy substrate P62 protein, so that the autophagy induction effect of the cotton rose hibiscus leaf extract in vitro and in vivo is demonstrated, 4 key autophagy related genes are knocked out in an AD nematode model by adopting RNAi bacteria, and the result shows that the neuroprotective effect of the cotton rose hibiscus leaf extract is obviously counteracted. In addition, when autophagy inhibitors 3-MA and Baf blocked autophagy activity, the degradation of APP, Tau and TauP301L proteins by Hibiscus mutabilis leaf extract was reversed in PC-12 cells. Hibiscus mutabilis leaf extract reduced cognitive and memory impairment and inhibited inflammatory responses and apoptosis associated with autophagy activation in 3 × Tg-AD mice. Therefore, the cotton rose hibiscus leaf extract has obvious treatment effect on NDs of various caenorhabditis elegans, cells and animal models through autophagy induction.
As a preferable scheme of the invention, the cotton rose leaf extract is a 65-80 v% ethanol extract of cotton rose leaves. Preferably, the cotton rose leaf extract is a 75% ethanol extract of cotton rose leaves.
As a preferable scheme of the invention, the dosage of the effective components of the medicine prepared from the cotton rose hibiscus leaf extract is more than or equal to 4.0 mg/kg. According to the animal experiment results of mice, when the dosage of the cotton rose hibiscus leaf extract is more than or equal to 50mg/kg, the cotton rose hibiscus leaf extract improves the cognitive and memory disorders of 3 × Tg-AD mice. The dosage of folium Hibisci Mutabilis extract is greater than or equal to 4.0mg/kg by conversion of adult body weight, mouse test body weight and specific surface area.
In a more preferred embodiment of the present invention, the amount of the leaf extract of Hibiscus Mutabilis is 4.0-30mg/kg, and may be 4.5mg/kg, 5mg/kg, 6mg/kg, 7mg/kg, 8mg/kg, 9mg/kg, 10mg/kg, 11mg/kg, 12mg/kg, 13mg/kg, 15mg/kg, 17mg/kg, 20mg/kg, 25mg/kg, etc.
Furthermore, the dose of the cotton rose leaf extract is 4.0-16.3mg/kg, and experiments show that when the concentration of the cotton rose leaf extract is more than or equal to 50-200mg/kg, the cotton rose leaf extract can effectively improve the cognitive and memory impairment of 3 × Tg-AD mice. Furthermore, the dose of the cotton rose hibiscus leaf extract is 8-16.3 mg/kg; more particularly, the dosage of the cotton rose hibiscus leaf extract is 16.3 mg/kg.
As a preferred scheme of the invention, the preparation method of the ethanol extract of the leaves of the cotton rose comprises the following steps: soaking folium Hibisci Mutabilis in ethanol, and performing ultrasonic treatment; and removing ethanol in the soaking solution after ultrasonic extraction, and then performing freeze-drying to obtain dry powder, namely the ethanol extract of the cotton rose hibiscus leaves.
As a preferred scheme of the invention, 2-5 times volume of ethanol is adopted to soak the leaves of the cotton rose hibiscus for 2-10 days. Preferably, the leaves of Hibiscus mutabilis undergo a crushing treatment.
Preferably, the solution is sonicated during soaking. More preferably, the sonication is performed 1-4 times, e.g. 2, 3 times during.
Preferably, the soaking solution is subjected to solvent removal by evaporation, such as rotary evaporation to dryness, to obtain ethanol extract of Hibiscus Mutabilis.
As a preferred embodiment of the present invention, the medicament is a medicament for preventing and/or treating neurodegenerative diseases. Preferably, the neurodegenerative disease is alzheimer's disease, parkinson's disease or huntington's disease.
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
(1) after the treatment of the cotton rose hibiscus leaf extract, the protein level of SQST-1/p62 (shown as GFP) in BC12921 nematodes is reduced, and the accumulation of GFP (shown as LGG-1/LC 3) positive points in DA2123 nematodes is increased, which shows that the cotton rose hibiscus leaf extract has strong autophagy induction activity on transgenic caenorhabditis elegans models.
(2) The cotton rose hibiscus leaf extract is used for obviously promoting the degradation of Abeta, delaying paralysis and improving the food perception disorder of neurons or genetically modified nematodes expressing human Abeta or Tau protein through muscles, which shows that the cotton rose hibiscus leaf extract can effectively improve the symptoms of AD and has the neuroprotective property aiming at the protein aggregation of caenorhabditis elegans.
(3) The treatment of the cotton rose hibiscus leaf extract can obviously prolong the life of wild type N2 nematodes, improve the physique and enhance the resistance to heat, pathogenic bacteria and oxidative stress, which shows that the cotton rose hibiscus leaf extract is one of promising components in the medicines for treating aging and aging-related diseases such as AD, PD and HD.
(4) By using PC-12 cells, the treatment of the cotton rose hibiscus leaf extract is found to obviously inhibit the cytotoxicity of Abeta fibers and APP, Tau and Tau P301L proteins in vitro, and the cognitive and memory functions and AD pathology of 3 × Tg-AD mice are also improved by the administration of the cotton rose hibiscus leaf extract. Therefore, the neuroprotective effect of the cotton rose leaf extract is verified and confirmed in various cells and animal models, and the neuroprotective effect of the cotton rose leaf extract in other models is further verified, so that the feasibility of clinical application is improved.
Drawings
FIG. 1 shows data of the induction of autophagy of caenorhabditis elegans by extracts of leaves of Hibiscus mutabilis;
FIG. 2 is data showing that Hibiscus mutabilis leaf extract exerts neuroprotective effects in models of nematodes of AD, PD and HD;
FIG. 3 is data of Abelmoschus manihot leaf extract to reduce Abeta-induced toxicity in an AD model of transgenic C.elegans;
FIG. 4 shows data of the longevity-extending and pressure-resisting capability-enhancing ability of the Hibiscus mutabilis leaf extract;
FIG. 5 is data showing that Hibiscus mutabilis leaf extract exerts neuroprotective effects in models of nematode worms AD, PD and HD by autophagy induction;
FIG. 6 is data showing that Hibiscus mutabilis leaf extract exerts neuroprotective effects in models of nematode worms AD, PD and HD by autophagy induction;
FIG. 7 shows data of autophagy induction in cells of Hibiscus mutabilis leaf extract;
FIG. 8 is a graph of data showing that Hibiscus mutabilis leaf extract inhibits A β fiber-induced cytotoxicity in cells and promotes degradation of APP, Tau and Tau-P301L proteins;
FIG. 9 shows that Hibiscus mutabilis leaf extract improves cognitive and memory impairment data in mice;
FIG. 10 is data of Abelmoschus manihot leaf extract to reduce A β and Tau symptoms in mice;
FIG. 11 shows data of the inhibition of the activation of NLRP3 inflammasome and the induction of autophagy activation in mice by Hibiscus mutabilis leaf extract.
Detailed Description
The present invention will be described in detail below with reference to the accompanying drawings.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and do not limit the invention.
Example 1
1. Preparation of materials
Soaking folium Hibisci Mutabilis in 75% ethanol twice the volume of folium Hibisci Mutabilis for 7 days, wherein the folium Hibisci Mutabilis is dried and pulverized, and performing ultrasonic treatment for 2 times, each for 30 min. After ultrasonic extraction, the soak solution is transferred to an evaporation dish or a rotary evaporator to remove most of the ethanol solvent. Then, the extract is made into dry powder by a freeze drying mode, namely the ethanol extract of the leaves of the cotton rose. Storing at-80 deg.C for use.
2. Testing
2.1 caenorhabditis elegans: strain, culture and synchronization
Caenorhabditis elegans is a relatively simple invertebrate with small size, short life span, and rapid cycle 3 days), high reproduction rate, easy culture, low cost, definite cell line and dissectionStructure and the like. More importantly, it has a complete and easily controlled nervous system, consisting of 302 neurons and approximately 5000 chemical synapses, giving it the ability to respond neurotoxically. Although transgenic mice, as more complex mammals, better mimic and represent the actual process of human NDs, they are slow in cycle, expensive and unsuitable for drug screening. Thus, nematodes have become a simple and reliable animal model in research in the fields related to neurodegenerative diseases and aging.
Wild type nematode strain N2, transgenic nematode strain BC12921[ rCes T12G3.1:: GFP + pCeh361], DA2123 [ lgg-1p:: GFP:: lgg-1+ rol-6(su1006) ], CL2331[ myo-3p:: GFP:: A-Beta (3-42) + rol-6(su1006) ], CL4176[ myo-3p:: A-Beta (1-42): let-8513 'UTR) + rol-6(su1006) ], CL2335[ pCL45 (Psnb-1:: Abeta 1-42::3' o::::::: + ld: + 2:: UTR GFP ], CL2122[ (ppd30.38) unc-54 (vector) + (L26) mtl-2: BR 70:: 70: 34-75: 34. sup.: stem-7: 34. sup.: 32. sup.: 34. sup. wt.% GFP, M35. sup. 3538) unc-54 (vector) + (L26), McMR 5232. mCP 5[ mCP ] mCP 5 ]: 5232:: 32: (mCP ] mCP 5:: 32: (mCP) and 75: (mCP) mCP 7: [ 10: (34: (mCP) mCP 7: (34:: 34. sup.: 9) (III) mCP 7: 34. sup. 34. sup. 34. sup. 34. sup. 34. sup. 34. sup. 34. sup. 34. sup. wt.: 9) stem K), NL5901[ unc-54p:: alphasynuclein:: YFP + unc-119(+) ], BZ555[ dat-1p:: GFP ], AM141[ unc-54p:: Q40:: YFP ], CF1553[ (pAD76) sod-3p:: GFP + rol-6(su1006) ], SJ 0[ hsp-6:: GFP ] and CL2166[ (pAF15) gst-4p:: GFP:: NLS ] all nematode strains were purchased from the C.elegans Genetic Center (CGC). Unless otherwise noted, caenorhabditis elegans were grown on standard Nematode Growth Medium (NGM) using E.coli OP50 as a food source in a constant temperature and humidity chamber at 20 ℃ and 60% humidity.
2.1 synchronization and culture of nematodes
All prior to the trial larvae at stage L1 were obtained by synchronization, as follows: eggs were separated from egg-laying worms using bleaching solution (0.5M NaOH + 1% NaClO), washed at least 3 times with M9 buffer, and then incubated overnight in M9 buffer. Subsequently, the synchronized L1 stage larvae were transferred to NGM plates containing OP50 for culture, and when the nematodes grew to L4 stage, they were transferred to fresh NGM plates supplemented with 5 mg/L5-fluoro-2' -deoxyuridine (FUDR) for continued culture to inhibit post-oviposition hatching of adult nematodes.
2.2 quantitative analysis of SQST-1/p62: GFP and GFP: LGG-1 fluorescence in the nematodes DA2123 and BC12921
Transgenic nematode strains DA2123 and BC12921 were used in this study to monitor nematode autophagy events as follows: the synchronized L1 stage nematode DA2123 and BC12921 larvae are spread on a NGM flat plate containing cotton rose leaf extract or Rap, cultured in an incubator at the temperature of 20 ℃ for 48h, then the nematodes are transferred to a microscope slide containing 100mM sodium azide for anesthesia, the microscope slide is lightly covered with a cover glass, and at least 30 GFP fluorescence pictures are observed and taken under an upright fluorescence microscope. ImageJ software was used to count the number of positive fluorescent spots in suture cells or intestinal cells of the DA2123 nematodes in the fixed area and to quantify the fluorescence intensity of the BC12921 nematodes. In addition, the expression of GFP protein was verified by detecting PE-GFP:LGG-1, GFP:LGG-1 and SQST-1/p62 by Western blotting.
2.3 assay of A.beta. (3-42) aggregation in CL2331 nematodes
The CL2331 strain was used to analyze the aggregation of nematode A.beta.3-42. Briefly, synchronized L1 larvae were treated with cotton rose hibiscus leaf extract at 15 ℃ to reach L4 late stage larvae. Then transferred to NGM plates containing Fudr and Hibiscus Mutabilis leaf extract to prevent offspring hatching, and cultured at 25 deg.C for 4 days. After treatment, nematodes were collected in M9 buffer, transferred to microscope slides containing 100mM sodium azide for anesthesia, covered gently with a cover slip, observed under an upright fluorescence microscope and photographed for at least 30 GFP fluorescence. ImageJ software was used to measure the number of A β (3-42) LGG-1 positive fluorescent spots in the fixed area.
2.4 test for A β -induced paralysis in CL4176 and CL2006
Transgenic nematode strains CL4176 and CL2006 which specifically express the human Abeta 1-42 protein through muscles are used for respectively carrying out acute or chronic paralysis experiments. The specific operation is as follows:
CL 4176: after the L1-stage nematodes are maintained and cultured in an incubator at 15 ℃ for 36h, the nematodes are quickly transferred to an incubator at 25 ℃ for further culture for 30h, and then the nematode state is observed under a microscope at any time. When more nematodes on the plate enter a paralyzed state, photographing and counting are started. The nematode can not move due to external mechanical stimulation (such as the nematode needle lightly touching the body) or head movement, and the body can not move, namely, the nematode is paralysis.
CL 2006: after the L1-stage nematodes were maintained in the 20 ℃ incubator for 52h, they were transferred to plates containing Fudr to prevent offspring hatching, and then they were cultured in the 20 ℃ incubator with fresh NGM plates being changed every two days. When the nematodes begin to enter the paralyzed state, the paralyzed number of the nematodes begins to be recorded, and statistics is carried out once every 24 hours.
2.5 food perception test
Food-sensing behavior analysis was performed to assess nematode neurological function. Nematodes move rapidly in plates without bacteria and slowly in bacterial turfs to feed themselves more efficiently. However, when the nervous function of nematodes is disrupted, their movement in bacterial lawns is slowed. NGM plates with or without OP50 will be prepared in advance, and the nematodes treated with cotton rose hibiscus leaf extract will then be transferred to plates with or without OP 50. To avoid stress, the nematode was allowed to stand for 90 seconds and then counted for the number of body bends in 20 seconds. The food perception capability is reflected by the deceleration rate, and the specific formula is as follows:
deceleration rate (N) Food-free food -N With food )/N No food (ii) a N represents the number of body bends in 20 s.
2.6 body bending test of NL5901 and AM141 nematodes
The synchronized L1 stage transgenic nematode strain NL5901 or AM141 was cultured on NGM plates with or without Hibiscus mutabilis leaf extract. On days 5 and 10 after adulthood, the treated nematodes were transferred to M9 buffer and left for 120 seconds to avoid interference with stress-related behavior. The number of body bends over 20 seconds was then observed and recorded under a stereomicroscope, while a representative video of nematode swimming was taken with Bandicam software.
2.7 fluorescent quantitation of alpha-synuclein and polyQ40 aggregates
NL5901 and AM141 nematode strains are used for analyzing the aggregation of alpha-synuclein and polyQ40 protein in the nematodes. Briefly, synchronized transgenic nematode strains NL5901 or AM141, stage L1, were cultured on NGM plates with or without cotton rose hibiscus leaf extract. After treatment, nematodes were collected in M9 buffer, transferred to microscope slides containing 100mM sodium azide for anesthesia, covered gently with a cover slip, observed under an upright fluorescence microscope and photographed for at least 30 GFP fluorescence. ImageJ software was used to measure the fluorescence intensity of each nematode α -synuclein:: YFP or polyQ40:: LGG-1.
2.8 treatment with 6-OHDA and quantitative determination of DA neurodegeneration
Caenorhabditis elegans BZ555 strain expressing GFP in DA neurons was treated with 6-OHDA to establish a PD model of DA neurodegeneration, in particular as follows: the L3 stage nematodes were transferred to NGM broth containing 50mM 6-OHDA, 10mM ascorbic acid and OP50 for 1h with gentle mixing every 10 minutes. After incubation, the cells were washed 3 more times with M9 buffer until the liquid was substantially clear or nearly clear. The nematodes were then transferred to NGM plates containing extracts of leaves of Hibiscus mutabilis or levodopa, cultured at 20 ℃ for 72h, collected with M9 buffer, transferred to microscope slides containing 100mM sodium azide for anesthesia, coverslipped gently, observed under an upright fluorescence microscope and photographed for at least 30 GFP fluorescence photographs. The GFP fluorescence intensity in the head fixation region of each nematode was measured using ImageJ software.
2.9 Life measurement
Prior to the experiment, nematodes had to be stably cultured for more than 3 generations without starvation. Synchronized L1 larvae were maintained in culture on NGM dishes for 52 hours to grow to late L4 or early adult stages. The nematodes were then transferred to fresh NGM dishes containing 200. mu.g/mL Hibiscus mutabilis leaf extract and 5mg/LFUDR to prevent hatching of the eggs. We define the first day of starting treatment with the extract of leaves of Hibiscus mutabilis as day 0 of the life test of adult nematodes and transfer the nematodes to corresponding fresh plates every 1-2 days during the period from day 0 to day 10 to ensure the efficacy of the drug. The life statistics were performed starting from the moment of normal nematode death (not more than day 10 at the latest) and once a day at a fixed time. If the body or head of the nematode is lightly stimulated with platinum wire, the nematode will not respond to any physical stimulus and will be defined as dead. For nematodes that escape the plate, rupture of the reproductive tract or spill of intestinal contents, statistics were not included. At least 60 nematodes per group need to be kept in a minimum statistical amount per life test.
2.10 quantification of pharyngeal and crawling function analysis
In the pharyngeal twitch and speed test, wild type N2 nematodes were treated with or without extracts of Hibiscus mutabilis according to the longevity test method. Treated nematodes were observed and analyzed under a stereomicroscope on days 5 and 10 of adulthood.
For pharyngeal function analysis, one pharyngeal pumping was defined as one contraction of the posterior sphere/mill, and the number of pharyngeal pumping events for the nematodes was counted in 20 seconds. And observing the crawling state of the nematodes under a stereoscopic microscope, and simultaneously acquiring the motion video of the nematodes by using Bandicam software. Mean and maximum nematode velocities were analyzed and quantified by ImageJ and wrMTrck Batch.
2.11 RNAi interference by caenorhabditis elegans
Single clones of RNAi bacteria were transferred to LB medium/ampicillin (50. mu.g/mL), shaken continuously overnight at 37 ℃ and induced to synthesize dsRNA by addition of isopropyl thiogalactoside (IPTG,5 mM). In order to inhibit 4 key autophagy-related genes (unc-51, bec-1, vps-34 and lgg-1) in nematodes, synchronized L1 nematodes were plated on NGM plates containing extracts of leaves of Hibiscus mutabilis and RNAi bacteria, and then maintained at 20 ℃ for culture, and nematodes were collected at corresponding time points to determine various indicators.
2.12 RNA extraction and qRT-PCR
Total nematode RNA was extracted using the RNAioso Plus reagent (TaKaRa) according to the manufacturer's instructions. Then, the DNA was transcribed with One-Step cDNA Synthesis Kit (Takara, 6110A), and 1. mu.g of total RNA was used as a template for reverse transcription into cDNA. The qRT-PCR was performed on a Bio-Rad CFX96 real-time system and a C1000 thermal cycler (Bio-Rad, CA, USA) using SYBR Green Dye (Takara) as a fluorescent probe. The transcription level of the gene was normalized by the transcription level of cdc 42. The primers used for qRT-PCR are listed in Table S1.
2.13 cell culture
PC-12 cells were obtained from American type culture Collection (ATCC, Rockville, Md., USA) and were selected for evaluation of the neuroprotective effects of extracts of Hibiscus mutabilis leaves. Stable GFP-RFP-LC 3U 87 cells were generously given by Baker of Xiaoming (university of Australian science, Australian, China). In this, PC-12 cells were cultured in DMEM basal medium containing 10% Fetal Bovine Serum (FBS) (Gibco, Rockville, Md., USA), 50U/mL penicillin and 50. mu.g/mL streptomycin (Invitrogen, Scotland, UK). GFP-RFP-LC 3U 87 cells were cultured in α -MEM basal medium supplemented with 10% FBS, 50U/mL penicillin, and 50 μ g/mL streptomycin. All cells were maintained in an incubator with 5% carbon dioxide, 75% humidity, 37 ℃.
2.14 preparation of Abeta (1-42) cellulose
1mg of lyophilized A β (1-42) peptide was dissolved in hexafluoroisopropanol (HFIP, Sigma), then re-lyophilized and stored at-80 ℃. The stored monomeric peptides were each dissolved in dimethyl sulfoxide (DMSO, Sigma) to a final concentration of 2mM and then used after 7 days of incubation at 37 ℃. The stock was finally diluted in sterile phosphate buffered saline (PBS, Sigma) at a concentration of 20. mu.M in the culture medium.
2.15 cell viability assay
Cell counting kit-8 (CCK-8, MedChemexpress, Monmouth Junction, NJ, USA) was used to detect cell viability. By 5X 10 3 Density per well cells were seeded into 96-well plates, and after cell treatment was complete, the old medium was removed and fresh medium containing 10 μ L CCK-8 solution was added to each well of the plate. Subsequently, the plate was gently mixed for 30 seconds and cultured at 37 ℃ for 2 to 4 hours in a cell culture chamber containing carbon dioxide at a concentration of 5%. Finally, the absorbance (OD) value of the solution was measured at 450nm using a rotation 3 imager (BioTek, VT Lab, USA). Cell viability was calculated using the following formula:
cell survival (%) ═ OD value Drug treatment OD value Control ×100。
2.16 quantitative analysis of GFP-LC3 fluorescent spots
The stabilized GFP-RFP-LC 3U 87 cells were seeded onto coverslips in 6-well plates. Treating cells with folium Hibisci Mutabilis extract, and polymerizing with 4%Formaldehyde (PFA) cells were fixed at room temperature for 20 minutes and then washed 2 times with PBS. After the slides were air dried, FluorSave was used TM Mounting medium (Calbiochem, San Diego, CA, USA) was mounted as a sheet. Then, the CCD digital camera is mounted at Spot RT3 TM Representative images of cells expressing the fluorescent spot of LC3 were observed and taken under an ECLIPSE 80i fluorescence microscope (Diagnostic Instruments, inc., Melville, NY, USA) and the number of GFP-LC3 spots per cell was measured in GFP positive cells. At least 150 cell counts were selected from 3 randomly selected regions.
2.17 Thioflavin T fluorescence assay
Freshly prepared stock solutions of Abeta (1-42) (dissolved at 2mM in DMSO) were removed and diluted to a final concentration of 20. mu.M with 100. mu.L of PBS buffer with or without Hibiscus mutabilis leaf extract. The mixture was then transferred to an incubator at 37 ℃ for 24 hours, 48 hours or 72 hours. After treatment, 10. mu.L of the mixture was transferred to a fluorescent 96-well plate, 190. mu.L of ThT solution (20. mu.M) was added thereto and mixed well, and then the mixture was transferred to an incubator at 37 ℃ for further incubation for 1 hour. After incubation was complete, the fluorescence intensity of each set of ThT solutions was measured at an excitation wavelength of 440nm and an emission wavelength of 470nm using a Cytation 3 microplate reader.
2.18 animals
3 × Tg-AD mice carrying the human mutant genes APPswe, Psen1 and TauP301L (strain: B6; 129-Tg [ APPSwe, tauP301L ] Psen1tm1Mpm/Mmjax, No.: 34830-JAX) were purchased from Jackson laboratories (Bar Harbor, ME, USA). 3 × Tg-AD mice (model mice) and C57BL/6J mice (wild-type normal mice) were housed in an SPF-rated animal house (humidity, 60%; temperature, 20-24 ℃) given a 12 hour light/dark cycle and freely available food and water. Male and female mice (20-22 g) of similar body weight were randomly selected and assigned a number and divided for study prior to dosing intervention. The groups in the study comprise a normal control group (normal mice are subjected to intragastric perfusion by normal saline), a model group (3 XTG-AD mice are subjected to intragastric perfusion by normal saline), a low-dose cotton rose hibiscus leaf extract group (3 XTG-AD mice are subjected to intragastric perfusion by cotton rose hibiscus leaf extract with the weight of 50mg/kg per kilogram), a medium-dose cotton rose hibiscus leaf extract group (3 XTG-AD mice are subjected to intragastric perfusion by cotton rose hibiscus leaf extract with the weight of 100 mg/kg per kilogram) and a high-dose cotton rose hibiscus leaf extract group (3 XTG-AD mice are subjected to intragastric perfusion by cotton rose leaf extract with the weight of 200mg/kg per kilogram). The mice of the normal control group, the model group and the treatment group of the cotton rose hibiscus leaf extract are irrigated with the same volume of normal saline or cotton rose hibiscus leaf extract solution once a day at 5-6 pm within 60 consecutive days, and the treatment sequence is random. Prior to sacrifice, the cognitive function of the mice was assessed using the Y-maze (YM) and Morris Water Maze (MWM) tests following the last dose of treatment. Subsequently, all mice were anesthetized with 10% chloral hydrate (4 ml/kg) and decapitated to separate brain tissue. Brain tissue from mice was stored at-80 ℃ for Western blotting experiments or fixed with 4% Paraformaldehyde (PFA) for immunohistochemistry experiments. All animal care and experimental procedures involved in this study were approved by the Animal Ethics Committee (AEC) of the southwest medical university.
2.19Y-maze test
The spontaneous alternation test was carried out in a symmetrical white plexiglas Y-shaped maze having three arms (20 cm long by 10 cm wide by 20 cm high) at an angle of 120 DEG, each of the three arms being designated A, B, C. Mice were placed distal to the a-arm and allowed to explore the maze for 5 minutes. The trajectory of the mouse was recorded with a camera mounted above the maze and a DigBehv animal behavior analysis system (shanghai jiliang software technologies ltd, shanghai, china). The percentage of the number of alternations (the number of entries into one arm different from the first two) was calculated using the following formula. (Alternatives/(Arm Entries-2)). 100.
2.20 Moris Water maze test
The Morris Water Maze (MWM) assay was used to evaluate spatial learning and memory performance in 3 × Tg-AD mice. The MWM system was equipped with a circular dark grey water basin (120 cm diameter; 50 cm height) filled with water and maintained at a temperature of 22-24 ℃. The pool was divided into four quadrants, with an escape platform (8 cm diameter) centered 2 cm below the water surface in the center of the third quadrant. Each mouse required training twice daily for 5 consecutive days prior to testing. During training, each mouse entered the water from one of the four quadrants and was allowed to find the platform and dwell on it for 10 seconds within 60 seconds. After training, the platform was removed, mice were placed in the water from the same quadrant, and the swimming trajectory of the mice within 60 seconds and the number of mice entering the quadrant of the original platform were recorded using the visotack rodent behavior analysis system (shanghai new raney information technology limited, shanghai, china). In addition, the time of the mouse in the quadrant of the original platform, the frequency of passing through the quadrant of the original platform and the distance of the mouse in the quadrant of the original platform are all measured by the system.
2.21 Western blot analysis (Westernblotting)
After the sample is treated, a sample of brain tissue from cells, nematodes or mice is lysed with RIPA buffer containing protease and phosphatase inhibitors. Protein concentration was measured by Quick Start TM Bradford 1 × Dye protein assay Reagent (Bio-Rad, Calif., USA). A mixture of 30. mu.g of total protein per sample was aspirated and added to SDS-PAGE for separation. Subsequently, the proteins separated on the gel were transferred to a polyvinylidene fluoride (PVDF) membrane. Thereafter, PDVF membranes were incubated with 5% skim milk at room temperature for 1 hour, followed by primary antibody at 4 ℃ overnight, followed by HRP-conjugated secondary antibody (1:2000) at room temperature for 1 hour, and proteins were detected with specific antibodies as listed in Table S2. Finally, the Western blot bands were visualized using UltraSignalTM ECL Western blot detection reagent (4A Biotech, Inc., Beijing, China) and detected using the ChemiDoc MP imaging System (Bio-Rad, Berkeley, Calif.). Finally, the intensity of the bands representing the relative expression level of the protein was quantified using ImageJ software.
2.22 immunohistochemistry
After the whole mouse brain was fixed in 4% Paraformaldehyde (PFA) for 48 hours, it was dehydrated in 95% ethanol and then frozen in Optimal Cutting Temperature (OCT) complex embedding medium. Subsequently, the frozen tissue was cut into a sheet including the hippocampus and fixed on a glass slide. The sections were deparaffinized and rehydrated by a series of incubations in xylene and ethanol. After reconstitution, antigen retrieval was performed in a humidity chamber using EDTA solution at pH9.0 and citric acid buffer at pH 6.0. The tissue sections were then cooled at Room Temperature (RT), and the antigen-reconstituted sections were subsequently incubated in 0.3% H2O2 in methanol for 30 minutes to quench the activity of endogenous peroxidase. Then, the extracted antigen sections were washed, incubated with the appropriate primary antibody at 27 ℃ for 1 hour, washed of excess antibody, and incubated with the appropriate secondary antibody at 27 ℃ for 30 minutes. After the secondary antibody incubation, sections were visualized with 3-3 Diaminobenzidine (DAB). Representative images were taken with an optical microscope (Nikon, japan) and optical density values representative of protein expression were analyzed with ImageJ software.
2.23 Elisa assay of A.beta.1-42
The expression level of A.beta.1-42 in the brain and serum of 3 × Tg-AD mice was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Rexin organism, RX 203110M). Briefly, mouse brain tissue and serum samples were prepared according to the protocol described in the ELISA kit. The supernatant was then processed in flat bottom 96 well ELISA plates according to the manufacturer's instructions and the absorbance OD was measured at 450nm using the rotation 3 microplate reader. The levels of A β (1-42) in brain and serum of 3 × Tg-AD mice are expressed in pg/mL. All experiments were repeated at least three times.
2.24 statistical analysis
Data expressed as mean ± Standard Deviation (SD) were analyzed using GraphPad Prism 6.0 software (San Diego, CA, USA), using one-way analysis of variance, followed by Tukey post-tests. The results shown are from at least three independent experiments. P <0.05 was considered statistically significant.
3. Results
3.1 Hibiscus mutabilis leaf extract induces autophagy of caenorhabditis elegans
A transgenic nematode strain DA2123 is used as a high-throughput screening model, and natural products with strong autophagy induction activity are screened from a Chinese herbal medicine library. It was reported that when autophagy was activated, LGG-1/ATG8 was sequestered on the membrane of autophagosomes and aggregated into spots, and thus the expression of this protein could serve as a marker event for the occurrence of autophagy. The treatment of the cotton rose hibiscus leaf extract (FHME) significantly increased the number of LGG-1: GFP positive spots in DA2123 nematode seam cells and intestinal cells, which is comparable to Rap, a typical potent autophagy activator, indicating that the cotton rose hibiscus leaf extract can effectively induce autophagy of nematodes (a and B in fig. 1). Meanwhile, Western blotting results showed that the ratio of Phosphatidylethanolamine (PE) -bound GFP:: LGG-1 (PE-GFP:: LGG-1) to non-lipidated GFP:: LGG-1 was significantly decreased (FIG. 1, E).
During autophagy, SQST-1/p62 protein, a substrate specific for autophagy, interacts with LC3 protein to infiltrate autophagosomes and is degraded in lysosomes, thereby indirectly reflecting the activity of autophagy. By utilizing the principle, the autophagy activity of the cotton rose hibiscus leaf extract is verified by utilizing a transgenic nematode strain BC12921 expressing SQST-1/p 62:GFPfusion protein in vivo. Compared with the control group, after 48 hours of treatment of the BC12921 nematodes by the cotton rose hibiscus leaf extract, the SQST-1/p62 shows that the GFP protein is obviously degraded and has statistical significance (C and D in figure 1). In addition, the expression level of GFP protein in BC12921 bodies is detected by Westernblotting, and the result shows that the extract of leaves of cotton rose hibiscus also reduces the SQST-1/p62: (F in figure 1) the protein level of GFP. qRT-PCR analysis showed that the treatment of the leaf extract of Hibiscus mutabilis significantly increased the mRNA levels of autophagy-related genes including unc-51 and vps-34 (G in FIG. 1) in the wild-type N2 nematodes. The results show that the cotton rose hibiscus leaf extract can induce autophagy of caenorhabditis elegans.
3.2 Hibiscus mutabilis leaf extract reduces Abeta and Tau-induced toxicity in AD model of transgenic C.elegans
Enhancing autophagy plays an important role in the prevention of various neurodegenerative diseases, including AD, PD and HD. In a wide range of past reports, a β plaque deposition is thought to play an important role in the pathogenesis of AD. Therefore, firstly, the inhibition effect of the hibiscus mutabilis leaf extract on the aggregation of A beta in the nematode body is researched by utilizing the transgenic nematode strain CL2331 for expressing human A beta (3-42) GFP protein in the somatic muscle cells of the nematode body in a temperature sensitive way. As shown in A and B in figure 3, the treatment of the cotton rose hibiscus leaf extract significantly reduced the number of Abeta (3-42) -GFP positive spots in CL2331 nematodes, indicating that the cotton rose hibiscus leaf extract can degrade Abeta (3-42) aggregates in vivo. In addition, paralysis induced by A.beta.aggregation toxicity was detected using transgenic CL4176 worms temperature-sensitively expressing A.beta. (1-42) protein in somatic muscle cells. As shown in A and C in figure 2, the paralysis rate of CL4176 nematodes is obviously reduced by 100-mL of the Hibiscus mutabilis leaf extract with 200. mu.g/mL, and the best effect is shown by 200. mu.g/mL of the Hibiscus mutabilis leaf extract. Therefore, 200 μ g/mL of Hibiscus mutabilis leaf extract was selected as the optimal therapeutic concentration in subsequent nematode experiments.
In order to prove the protection effect of the cotton rose hibiscus leaf extract on A beta-induced toxicity, transgenic nematode CL2006 which directionally expresses A beta (1-42) protein in body wall muscle cells is adopted. It was found that treatment with extracts of cotton rose hibiscus leaves also significantly delayed paralysis of the CL2006 nematodes (fig. 3D). Furthermore, we tested A β -induced impairment of food perception using transgenic nematode strain CL2335, which expresses A β (1-42) protein temperature-sensitively in pan-neurons, and its control strain CL 2122. As expected, the CL2335 nematodes showed a defect in food perception, mainly in slowing down the rate of decline. However, the treatment with hibiscus mutabilis leaf extract effectively protected this defect (B in fig. 2). In addition, a transgenic nematode strain BR5270 expressing the human Tau protein in pan-neurons and its control strain BR5271 were used to evaluate the neurotoxicity of Tau. Food perception test results showed that the neuron-damaged BR5270 nematodes showed a defect in food perception, which was significantly improved by treatment with the extract of cotton rose leaves, as evidenced by a reduction in speed (C in fig. 2). Taken together, the results indicate that hibiscus mutabilis extract exhibits potent neuroprotective effects on abeta and Tau-induced c.
3.3 Hibiscus mutabilis leaf extract inhibits alpha-synuclein pathology and inhibits DA degeneration in nematode PD model
There is increasing evidence that impairment of autophagy function is closely associated with PD, and enhancement of autophagy may improve the symptoms of PD. In this study, whether extracts of Hibiscus mutabilis improve the pathological state of alpha-synuclein was examined by using transgenic NL5901 nematodes expressing human alpha-synuclein and Yellow Fluorescent Protein (YFP) fusion proteins in somatic muscle cells. The results showed that the YFP intensity was significantly decreased in NL5901 nematodes treated with the cotton rose leaf extract at 5 and 10 days (D and E in fig. 2), indicating that the cotton rose leaf extract can inhibit the accumulation of alpha-synuclein. During senescence, the locomotor capacity of NL5901 nematodes decreases with aggregation of α -synuclein. However, treatment with cotton rose hibiscus leaf extract significantly improved the motor ability defect of NL5901 nematodes, which is mainly reflected in the number of body bends of the nematodes within 20 seconds (F in fig. 2). The results show that the treatment of the cotton rose hibiscus leaf extract can improve the pathology of alpha-synuclein in the caenorhabditis elegans PD model.
In addition, neurotoxin-induced degeneration of DA neurons is another important pathological hallmark of PD. Therefore, the dopamine neuron is labeled by the specific expression of GFP of the transgene nematode BZ555 under the action of the dat-1 promoter, and can be directly observed under a fluorescence microscope. Then 6-OHDA is used for inducing selective apoptosis of DA neurons of BZ555 worms, so that another PD model is established, and whether the cotton rose hibiscus leaf extract can inhibit DA neuron damage or not is further researched. The results indicate that the GFP intensity of the 6-OHDA-treated BZ555 nematodes is significantly lower than that of untreated BZ555 nematodes, indicating that 6-OHDA causes severe damage to DA neurons. However, treatment with cotton rose hibiscus leaf extract significantly inhibited 6-OHDA-induced neurological damage, with effects similar to levodopa (G and H in fig. 2). It has also been reported that 6-OHDA-induced nematodes also cause a dysfunction in food perception due to DA neuron damage. Therefore, it was further investigated whether the extract of leaves of Hibiscus mutabilis could improve the food perception disorder of 6-OHDA-induced BZ555 nematode. As shown by I in FIG. 2, the 6-OHDA-induced deceleration rate of BZ555 nematode was significantly reduced to 13% compared to the control group, while the treatment with the extract of Hibiscus mutabilis leaf or L-Dopa showed significant recovery of the deceleration rate to 50.3% and 47.2%, respectively. The results show that the extract of leaves of cotton rose hibiscus exerts a neuroprotective effect in the PD model of caenorhabditis elegans.
3.4 Hibiscus mutabilis leaf extract inhibits the aggregation of polyQ40 and improves nematode motility
The transgenic caenorhabditis elegans AM141 is utilized to research whether the Hd-related pathological and behavioral defects can be improved by the Hd leaf extract. This nematode strain specifically expresses a polyglutamine repeat (polyQ40) driven by the unc-54 promoter in muscle cells and mimics the HD-like phenotype. As shown by J, K in figure 2 and E in figure 3, the polyQ40 aggregates in the AM141 nematodes gradually accumulated with the increase of age, but the number of polyQ40 aggregates was significantly reduced on the 5 th and 10 th days after the treatment with the cotton rose hibiscus leaf extract, which suggests that the cotton rose leaf extract can inhibit the expression of polyQ40 in the AM141 nematodes. In addition, the movement ability of AM141 worms was significantly improved by treatment with the extract of cotton rose leaves, which significantly improved the movement ability of AM141 nematodes (L in FIG. 2). The results show that treatment with Hibiscus mutabilis leaf extract can alleviate polyQ40 aggregation and improve behavioral deficits in the caenorhabditis elegans HD model.
3.5 Hibiscus mutabilis leaf extract prolongs the life and improves health of wild type nematode N2
Aging is a major risk factor for the development of neurodegenerative diseases. Therefore, the effect of the cotton rose leaf extract on caenorhabditis elegans senescence was examined. Compared with the control group, the extract of leaves of Hibiscus mutabilis can prolong the life of wild type N2 nematode, with average life prolonging rate of 11.1% (FIG. 4A). Previous studies have shown that the age-related phenotypes currently known, such as pharyngeal pumping behavior and motor capacity, decrease with age, and that lipofuscin accumulates with age. Therefore, whether the cotton rose hibiscus leaf extract improves nematode health was investigated by assessing feeding and locomotor ability of wild-type N2 nematodes. As shown in B in figure 4, the treatment of the N2 nematodes by the cotton rose hibiscus leaf extract can significantly improve the pharyngeal pumping rate on the 5 th day and the 10 th day, which indicates that the cotton rose hibiscus leaf extract delays the decline of the pharyngeal muscle function with age. Furthermore, by measuring body curvature, mean velocity and maximum velocity within 20s of nematodes, we found that the cotton rose hibiscus leaf extract also significantly enhanced the locomotor ability of the N2 nematodes, young (5 days old) and old (10 days old) (C-E in fig. 4). In addition, treatment with Hibiscus mutabilis leaf extract significantly reduced the intestinal lipofuscin deposition of N2 worm (F in FIG. 4). In conclusion, the cotton rose hibiscus leaf extract can prolong the life of caenorhabditis elegans and delay senescence-associated phenotypes, which indicates that the cotton rose hibiscus leaf extract has anti-aging effect.
3.6 the extract of leaves of Hibiscus mutabilis enhances the anti-stress ability of caenorhabditis elegans
There is increasing evidence that resistance to external stimuli is closely related to the aging process and neurodegenerative diseases. Caenorhabditis elegans, which have been extended in life by genetic or non-genetic manipulation, generally exhibit greater resistance to stress. Therefore, we investigated whether the extract of leaves of Hibiscus mutabilis would improve the resistance of caenorhabditis elegans to heat, pathogenic bacteria and oxidative stress. As shown in G of FIG. 4, the survival rate of N2 nematodes was significantly improved by the treatment of Hibiscus mutabilis leaf extract under the heating condition of 35 deg.C. Molecular chaperones of Heat Shock Proteins (HSPs) are involved in the repair of misfolded proteins and contribute to cellular homeostasis. We found that treatment with hibiscus mutabilis leaf extract significantly increased HSP-6:GFPfluorescence intensity, representing expression of HSP-6 protein in transgenic SJ4100 strain (J in FIG. 4). In addition, the cotton rose hibiscus leaf extract also inhibited the mortality of wild-type N2 nematodes fed with pseudomonas aeruginosa (PA14), indicating that cotton rose hibiscus leaf extract enhanced nematode resistance to pathogenic stress (H in fig. 4). In agreement, the cotton rose hibiscus leaf extract increased the expression of detoxification-associated protein GST-4 in transgenic CL2166 nematodes (fig. 4, K). In addition, the cotton rose hibiscus leaf extract also improved the resistance of nematodes to oxidative stress, which is reflected in the improved survival rate of N2 nematodes under oxidative stress induced by 20mM H2O2, and the up-regulated expression of SOD-3:: GFP protein in transgenic CF1553 nematodes (I and L in fig. 4). The results show that the cotton rose hibiscus leaf extract can improve the resistance of the nematodes to heat, pathogenic bacteria and oxidative stress.
3.7 Hibiscus mutabilis leaf extract exerts neuroprotective effects in model of AD, PD and HD nematodes by autophagy induction
Next, it was investigated whether the extract of leaves of cotton rose hibiscus exerts neuroprotective effects on nematodes by activating autophagy. Firstly, RNAi bacteria are utilized to inhibit the expression of 4 key autophagy-related genes bec-1, unc-51, vps-34 and lgg-1 in a nematode AD model, and then the paralysis rate of CL4176 nematodes and the deceleration rate of BR5270 nematodes are respectively determined. As shown in FIG. 5A and FIG. 6A, treatment with Hibiscus mutabilis leaf extract significantly reduced the paralysis rate of CL4176 insect fed with control bacterium HT 115. However, feeding RNAi bacteria successfully counteracted the ameliorating effect of extracts of cotton rose hibiscus leaves on abeta-toxic protein-induced paralysis in CL4176 nematodes. Similarly, when BR5270 nematodes were fed with RNAi bacteria of these 4 key autophagy-related genes, the improvement effect of hibiscus mutabilis leaf extract on Tau-induced food perception behavior deficiency was also reversed (B in fig. 5). These results indicate that extracts of leaves of Hibiscus mutabilis may exert therapeutic effects against AD on nematodes by activating autophagy. Then, we performed similar RNAi bacterial feeding experiments to study the association between the autophagy induced by Hibiscus mutabilis leaf extract and the anti-PD and anti-HD effects. The results show that the previous cotton rose hibiscus leaf extract reduced the accumulation of NL5901 nematode alpha-synuclein alpha protein and improved dyskinesia (C and D in fig. 5 and B in fig. 6), DA degeneration of BZ555 nematode (E in fig. 5 and C in fig. 6), and improvement of polyQ40 accumulation of AM141 nematode were all counteracted by down-regulating 4 key autophagy genes by RNAi bacteria (fig. 5F and 6D). The data indicate that the neuroprotective effects provided by cotton rose hibiscus leaf extract in models of AD, PD and HD nematodes all depend on inducing autophagy.
3.8 Hibiscus mutabilis leaf extract induces autophagy in stabilized GFP-RFP-LC 3U 87 cells and PC-12 cells
To confirm whether the extract of leaves of Hibiscus mutabilis induces autophagy in vitro, stable GFP-RFP-LC 3U 87 cells were used to detect autophagy activity after the treatment of the extract of leaves of Hibiscus mutabilis. In the part, the cytotoxicity of the cotton rose hibiscus leaf extract on RFP-LC 3U 87 cells is firstly detected by using a CCK-8 kit, no obvious cytotoxicity exists below 31.3 mu g/mL, and the cotton rose hibiscus leaf extract with 7.8 mu g/mL has strong proliferation effect (A in figure 7). Subsequently, we tested autophagy of less than 31.3 μ g/mL of Hibiscus mutabilis leaf extract in RFP-LC 3U 87 cells. As shown in B and C of FIG. 7, the dose-dependent increase of the ratio of the number of GFP-LC3 fluorescent spots was observed in the extract of Hibiscus mutabilis leaves, indicating that the extract of Hibiscus mutabilis can induce autophagy in cells. Subsequently, whether the cotton rose hibiscus leaf extract can induce autophagy of nerve cells is further determined. Similarly, the cytotoxicity of Hibiscus mutabilis leaf extract in PC-12 cells was first examined. The results show that the cotton rose leaf extract obviously increases the cell activity at 2.0-62.5 mu g/mL, and the cotton rose leaf extract with 7.8 mu g/mL also shows the highest cell activity (D in figure 7). Then, we tested the expression levels of p62, LC 3-I and LC 3-II proteins by Western blotting. The results show that the extract of leaves of Hibiscus mutabilis dose-dependently reduced the expression of p62 protein in PC-12 cells and increased the ratio of LC 3-II/LC 3-I (E-G in FIG. 7). The result shows that the cotton rose hibiscus leaf extract can induce autophagy of GFP-RFP-LC 3U 87 cells and PC-12 cells.
3.9 Hibiscus mutabilis leaf extract inhibits A beta fiber-induced cytotoxicity in PC-12 cells
In order to explore whether the cotton rose hibiscus leaf extract plays a neuroprotective role in vitro, the improvement effect of the cotton rose hibiscus leaf extract on AD-related diseases is researched by adopting PC-12 cells. The formation of amyloid fibrils of a β is a major neuropathological marker of AD. In this study, inhibition of Abelmoschus manihot leaf extract on A β fibril formation was examined by ThT fluorescence. As shown in A in figure 8, the fluorescence intensity of ThT is weakened in a dose-dependent manner in 24h, 48h and 72h by using the cotton rose hibiscus leaf extract with different concentrations, which shows that the cotton rose hibiscus leaf extract can inhibit the formation of Abeta (1-42) fibers. In addition, there is increasing evidence that abnormal accumulation of a β fibers leads to neuronal degeneration and death. In order to research whether the folium Hibisci Mutabilis extract can reduce the cytotoxicity of Abeta fibril on nerve cells, an Abeta fibril induction model is used for constructing a nerve cell injury model, and then the treatment effect of the folium Hibisci Mutabilis extract on the model is detected by using a CCK-8 and PI/Hoechst staining method. As shown in B of FIG. 8, A β (1-42) fibrils significantly decreased the cell survival of PC-12 cells, while the cotton rose leaf extract dose-dependently increased the cell survival at a concentration range of 2-8 μ g/mL after drying. In addition, PI/Hoechst staining showed that Hibiscus mutabilis leaf extract significantly reduced the number of PI-positive cells in A β (1-42) -induced PC-12 cells (C in FIG. 8). The result shows that the cotton rose hibiscus leaf extract can destroy the formation of the Abeta (1-42) fibers and reduce the cytotoxicity induced by the Abeta (1-42) fibers in cells.
3.10 Hibiscus mutabilis leaf extract inhibits the expression of APP, Tau and Tau-P301L proteins in PC-12 cells
It is well known that a β is produced by proteolytic cleavage of Amyloid Precursor Protein (APP) by β -and γ -secretases, and that up-regulation of APP promotes the pathogenesis of AD by promoting a β production. Therefore, we examined whether the extract of leaves of Hibiscus mutabilis could reduce the production of A β by inhibiting the expression of APP in vitro. First, fluorescence microscopy analysis showed that the extract of leaves of Hibiscus mutabilis did not affect the transfection effect of pEGFP-N1 in PC-12 cells. We then used the pEGFP-N1-APP plasmid transfection to transiently over-express APP protein in PC-12 cells. As shown in D in FIG. 8, PC-12 cells transfected with pEGFP-N1-APP exhibited higher GFP intensity than control cells, indicating that the APP protein was overexpressed in PC-12 cells. However, the intensity of GFP is obviously reduced after the treatment of the cotton rose hibiscus leaf extract, which shows that the cotton rose hibiscus leaf extract can inhibit the expression of APP in vitro. Furthermore, neurofibrillary tangles (NFTs) composed of hyperphosphorylated Tau are another major pathological hallmark of AD. Then, we investigated whether or not the extract of leaves of Hibiscus mutabilis inhibited the expression of Tau and Tau-P301L proteins using PC-12 cells transiently transfected with pRK5-EGFP or pRK 5-EGFP-Tau-P301L. As shown by E-F in FIG. 8, GFP intensity, which represents the expression level of Tau or Tau-P301L, was significantly decreased in PC-12 cells after treatment with a leaf extract of Hibiscus mutabilis. All data show that the extract of the leaves of the cotton rose hibiscus can inhibit the expression of APP, Tau and Tau-P301L protein in vitro.
3.11 Hibiscus mutabilis leaf extract promotes degradation of APP, Tau and Tau-P301L proteins by inducing autophagy in PC-12 cells
To investigate whether the cotton rose hibiscus leaf extract promotes the degradation of AD-associated proteins by activating intracellular autophagy, autophagy was blocked using autophagy inhibitors 3-MA and Baf, and then the expression of APP, Tau and Tau-P301L proteins was assessed by fluorescence microscopy analysis. We observed that the fluorescence intensity of PC-12 cells transfected with pEGFP-N1-APP, pRK5-EGFP-Tau or pRK5-EGFP-Tau-P301L plasmid was significantly reduced after treatment with Hibiscus mutabilis leaf extract, while autophagy inhibitors, including 3-MA and Baf, significantly counteracted the effect of Hibiscus mutabilis leaf extract on the degradation of AD-associated proteins in PC-12 cells. In addition, Western blotting with GFP antibody was further performed to examine the expression of APP, Tau and Tau-P301L proteins. The results show that 3-MA and Baf obviously inhibit the clearance effect of the cotton rose hibiscus leaf extract on APP, Tau and Tau-P301L proteins (G-I in figure 8). The result shows that the cottonrose hibiscus leaf extract promotes the degradation of AD-related proteins in vitro through autophagy induction.
3.12 Hibiscus mutabilis leaf extract improves cognitive and memory disorders in 3 × Tg-AD mice
A three transgenic 3 x Tg-AD model mouse expressing three mutant transgenes (i.e., PS1M146V knock-in, APPS we and tauP301L) is currently the most popular AD mouse model because it presents a β and Tau lesions, neuroinflammation, cognitive decline and memory impairment in an age-dependent manner. Here, the neuroprotective effect of Hibiscus mutabilis leaf extract on 6-month old 3 × Tg-AD mice was studied. Cognitive ability was first assessed in the study using the Y Maze (YM) test. As shown in A and B in FIG. 9, the number of times 3 × Tg-AD mice entered the new arm was significantly reduced compared to WT mice, indicating that the cognitive ability of 3 × Tg-AD mice was impaired. However, the percentage of 3 × Tg-AD mice that entered the new arm after treatment with cotton rose hibiscus leaf extract significantly increased in a dose-dependent manner. These data indicate that extracts of Hibiscus mutabilis leaves can improve spatial working memory in 3 × Tg-AD mice.
Next, the Morris Water Maze (MWM) test was used to further evaluate spatial learning and memory. During training, escape latencies, i.e. the time at which the mouse found the hidden platform, were recorded. It was observed that escape latency of WT mice decreased significantly in five consecutive days of training, with the value on day five (39.0%) being only 43.3% of the value on day one (90.0%). In contrast, the escape latency for the model group to find the hidden platform (83.8%) was still 93.1% of the first day (90.0%) and 2.15 times the WT group time, indicating that the learning ability of the 3 × Tg-AD mice was impaired (C and D in fig. 9). In contrast, the escape latency of the last training day was also dose-dependently decreased in 3 × Tg-AD mice treated with cotton rose hibiscus leaf extract at doses of 50, 100 and 200mg/kg, which were 45.8%, 27.1% and 17.1%, respectively (C and D in fig. 9). In addition, the mean time percentage in the target quadrant, the frequency of crossing the original platform quadrant and the mean distance percentage in the target quadrant were all decreased in 3 × Tg-AD mice compared to WT mice, which were successfully prevented by treatment with extracts of cotton rose hibiscus leaf (E-G in figure 9). The data show that the cotton rose hibiscus leaf extract improves the cognitive and memory disorders of 3 XTG-AD mice.
3.13 Hibiscus mutabilis leaf extract for alleviating Abeta and Tau disorders in 3 XTG-AD mice
A β plaques and intracellular NFTs are the major characteristic lesions of AD. In order to research whether the extract of cotton rose hibiscus leaves can improve the A beta and NFTs pathological changes of 3 XTg-AD mice, the expression of the A beta and p-Tau protein is detected by an immunohistochemical method. The results showed that 3 × Tg-AD mice had higher levels of A β deposition and p-Tau protein expression in hippocampus and cerebral cortex (A in FIG. 10) compared to WT mice, which is consistent with previous results. In contrast, significant reductions in Abeta deposition and p-Tau levels were observed in 3 XTG-AD mice treated with Hibiscus mutabilis leaf extract (A in FIG. 10). In addition, brain tissue and serum A β (1-42) levels were assessed by ELISA. The results showed that the brain tissue and serum A.beta. (1-42) content of 3 × Tg-AD mice was increased compared to WT mice, and that treatment with Hibiscus mutabilis leaf extract reversed this phenomenon significantly (B and C in FIG. 10). In addition, Western blotting showed that Hibiscus mutabilis leaf extract also prevented abnormal elevated expression levels of A β and p-tau proteins in the brains of 3 × Tg-AD mice (D-F in FIG. 10). These results suggest that treatment with extracts of cotton rose hibiscus leaves has a positive effect on improving abeta plaque formation and Tau phosphorylation in 3 x Tg-AD mice.
Previous reports have shown that accumulation of a β oligomers and p-Tau may be responsible for neurological damage. The present study examined neuronal health by HE and Nissl staining. HE staining results showed that in untreated 3 × Tg-AD mice, neurons in the hippocampus and cerebral cortex were largely lost, and many of the remaining neurons were shown to be basophilic, nuclear, deep-stained and shriveled. However, in the hippocampus (CA1-CA2), treatment with an extract of Hibiscus mutabilis leaves significantly increased the number of surviving neurons and decreased the number of basophilic neurons (H in FIG. 10). In addition, Nissl staining showed that the neurones Nissl body of hippocampus and cerebral cortex was significantly increased and volume was larger after treatment with the Hibiscus mutabilis leaf extract, indicating that the structure and function of neurones were improved after treatment with the Hibiscus mutabilis leaf extract (I in FIG. 10). In addition, in order to further clarify the intrinsic molecular mechanism of the lesion, a protein Bax promoting apoptosis and a protein Bcl-2 inhibiting apoptosis in brain tissue were detected by Western blotting. We observed a significant increase in Bax/Bcl-2 ratio in 3 XTG-AD mice, which was reversed after treatment with extracts of Hibiscus mutabilis leaves (D and G in FIG. 10). Taken together, these data indicate that Hibiscus mutabilis leaf extract can reduce the pathological changes in 3 × Tg-AD mice.
3.14 Hibiscus mutabilis leaf extract inhibits activation of NLRP3 inflammasome and induces activation of autophagy in 3 × Tg-AD mice
The NLRP3 inflammasome is an obvious inflammatory body and consists of a proteolytic complex formed by NLRP3, ASC and Caspase-1, leads to the generation of Caspase-1 mediated Interleukin (IL) -1 beta and IL-18 in microglia, and finally promotes the development and the progress of AD. In the research, the inhibition effect of the cotton rose hibiscus leaf extract on NLRP3 inflammasome of 3 XTg-AD mice is further researched. Western blotting results show that the expression of 5 key NLRP3 inflammation related proteins including NLRP3, Caspase-1, ASC, IL-1 beta and IL-18 is obviously reduced in 3 × Tg-AD mice (shown in a figure 11, A-F), and that the cotton rose hibiscus leaf extract inhibits NLRP3 inflammation bodies in vivo. Furthermore, it was found that extracts of leaves of Hibiscus mutabilis induced autophagy in 3 XTg-AD mice, as evidenced by a decrease in p62 protein expression and an increase in LC3B levels in brain tissue (A, G and H in FIG. 11), consistent with the observations of C.elegans and PC-12 cells. The result shows that the cotton rose hibiscus leaf extract can inhibit NLRP3 inflammasome and activate autophagy of 3 × Tg-AD mice.
4. Summary of the invention
(1) Extensive and preliminary screening using a transgenic C.elegans model revealed that extracts of Hibiscus mutabilis have strong autophagy-inducing activity, as evidenced by a decrease in the protein levels of SQST-1/p 62:GFPin BC12921 nematodes and an increase in the accumulation of GFP:LGG-1/LC 3 positive spots in DA2123 nematodes.
(2) The neuroprotective effect of the cotton rose leaf extract is determined by adopting a plurality of mature caenorhabditis elegans models, the cotton rose leaf extract treatment obviously promotes A beta degradation, delays paralysis, and improves food perception disorder of transgenic nematodes expressing human A beta or Tau protein through neurons or muscles, and the data indicate that the cotton rose leaf extract can effectively improve AD symptoms and has the neuroprotective property aiming at protein aggregation of the caenorhabditis elegans. This is shown by the reduced accumulation of alpha-synuclein and polyQ40 aggregates, improved dyskinesia, and recovery of neurons from nematodes expressing alpha-synuclein or polyQ40 after extraction with cotton rose hibiscus leaf extracts, which all demonstrated similar results in the PD and HD models of C.elegans. In conclusion, it was determined that the extract of leaves of Hibiscus mutabilis has a neuroprotective effect on aggregate-associated NDs.
(3) The treatment of the cotton rose hibiscus leaf extract can obviously prolong the life of wild type N2 nematodes, improve the physique and enhance the resistance to heat, pathogenic bacteria and oxidative stress, and the results show that the cotton rose hibiscus leaf extract is one of promising components in the medicaments for treating aging and aging-related diseases (such as AD, PD and HD).
(4) The most common AD in NDs was selected to study the neuroprotective efficacy of Hibiscus mutabilis leaf extract in other models, and by using PC-12 cells, it was found that treatment with Hibiscus mutabilis leaf extract significantly inhibited the cytotoxicity of Abeta fibers and APP, Tau and Tau P301L proteins in vitro. In addition, it was found that cognitive and memory functions as well as AD pathology in 3 × Tg-AD mice were also improved by administration of Hibiscus mutabilis leaf extract. Therefore, the neuroprotective effect of the cotton rose leaf extract is verified and confirmed in various cells and animal models, and the neuroprotective effect of the cotton rose leaf extract in other models is further verified, so that the feasibility of clinical application is improved.
(5) Misfolded proteins associated with NDs are degraded mainly by autophagy. The cotton rose hibiscus leaf extract can promote the formation of GFP-LC3 spots in stable GFP-RFP-LC 3U 87 cells, increase the expression of LC3B in PC-12 cells and 3 × Tg-AD mice and reduce the expression of autophagy substrate P62 protein, and further verifies the autophagy induction effect of the cotton rose hibiscus leaf extract in vitro and in vivo. In order to determine whether the autophagy induction is related to the neuroprotective effect of the cotton rose leaf extract in various models, 4 key autophagy related genes are knocked out in an AD nematode model by adopting RNAi bacteria, and the result shows that the neuroprotective effect of the cotton rose leaf extract is obviously counteracted. Furthermore, when autophagy inhibitors 3-MA and Baf blocked autophagy activity, the degradation of APP, Tau and Tau P301L proteins by extracts of Hibiscus mutabilis was reversed in PC-12 cells. In 3 × Tg-AD mice, extracts of leaves of Hibiscus mutabilis reduced cognitive and memory impairment and inhibited inflammatory responses and apoptosis associated with autophagy activation. The results show that the cotton rose hibiscus leaf extract has obvious treatment effect on NDs of various caenorhabditis elegans models, cells models and animal models through autophagy induction.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principles of the present invention are intended to be included within the scope of the present invention.
Claims (7)
1. The application of the cotton rose hibiscus leaf extract in the medicines for treating neurodegenerative diseases is characterized in that the cotton rose hibiscus leaf extract is a cotton rose hibiscus leaf ethanol extract.
2. The use of the cotton rose hibiscus leaf extract as claimed in claim 1, wherein the cotton rose hibiscus leaf extract is a 65-80 v% ethanol extract of cotton rose hibiscus leaves.
3. The use of the cotton rose hibiscus leaf extract as claimed in claim 1, wherein the dosage of the cotton rose hibiscus leaf extract is greater than or equal to 4.0 mg/kg.
4. The use of the HlblSClSClSClSCHI leaf extract in the medicament for treating neurodegenerative diseases according to claim 3, wherein the dose of the HlblSCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCLE leaf extract is 4.0-25 mg/kg.
5. The use of the HlblSClSClSClSCHI leaf extract in the medicament for treating neurodegenerative diseases according to claim 4, wherein the dose of the HlblSCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCLE leaf extract is 4.0-16.3 mg/kg.
6. The use of the HlblSClSClSClSCHI leaf extract in the medicament for treating neurodegenerative diseases according to claim 5, wherein the dose of the HlblSCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCHISCLE leaf extract is 8-16.3 mg/kg.
7. The use of the extract of leaves of Hibiscus mutabilis according to any one of claims 1 to 6 in the preparation of a medicament for treating neurodegenerative disease, wherein the ethanol extract of leaves of Hibiscus mutabilis is prepared by:
soaking folium Hibisci Mutabilis in ethanol, and performing ultrasonic treatment; removing ethanol in the soaking solution after ultrasonic extraction, and then performing freeze-drying to obtain dry powder, namely the ethanol extract of the leaves of the cotton rose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210461930.1A CN114931591A (en) | 2022-04-28 | 2022-04-28 | Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210461930.1A CN114931591A (en) | 2022-04-28 | 2022-04-28 | Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114931591A true CN114931591A (en) | 2022-08-23 |
Family
ID=82863441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210461930.1A Pending CN114931591A (en) | 2022-04-28 | 2022-04-28 | Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114931591A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150050363A1 (en) * | 2013-08-15 | 2015-02-19 | Macau University Of Science And Technology | Novel autophagy enhancer for treatment of neurodegenerative diseases |
CN112870184A (en) * | 2021-04-21 | 2021-06-01 | 澳门大学 | Application of rheum emodin in preparing medicine for treating or improving neurodegenerative diseases |
CN114617914A (en) * | 2020-12-10 | 2022-06-14 | 湖南翱康生物科技有限公司 | Novel medicine for preventing and treating neurodegenerative diseases |
-
2022
- 2022-04-28 CN CN202210461930.1A patent/CN114931591A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150050363A1 (en) * | 2013-08-15 | 2015-02-19 | Macau University Of Science And Technology | Novel autophagy enhancer for treatment of neurodegenerative diseases |
CN114617914A (en) * | 2020-12-10 | 2022-06-14 | 湖南翱康生物科技有限公司 | Novel medicine for preventing and treating neurodegenerative diseases |
CN112870184A (en) * | 2021-04-21 | 2021-06-01 | 澳门大学 | Application of rheum emodin in preparing medicine for treating or improving neurodegenerative diseases |
Non-Patent Citations (1)
Title |
---|
国家药典委员会, 中国医药科技出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Qi et al. | Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model | |
Xu et al. | Caspase-1 inhibitor exerts brain-protective effects against sepsis-associated encephalopathy and cognitive impairments in a mouse model of sepsis | |
Han et al. | Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity | |
Chen et al. | Tau and neuroinflammation in Alzheimer’s disease: Interplay mechanisms and clinical translation | |
Kim et al. | Protective effect of exercise training against the progression of Alzheimer’s disease in 3xTg-AD mice | |
Mookherjee et al. | GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model | |
Aguilar-Calvo et al. | Prion and prion-like diseases in animals | |
Bai et al. | A Maitake (Grifola frondosa) polysaccharide ameliorates Alzheimer's disease-like pathology and cognitive impairments by enhancing microglial amyloid-β clearance | |
Zyśk et al. | Long-term effects of traumatic brain injury in a mouse model of Alzheimer’s disease | |
US20190015361A1 (en) | Polytherapy modulating cathelicidin gene exprtession modulation for the treatment of alzheimer's disease and other conditions | |
Chen et al. | Long-term oral administration of hyperoside ameliorates AD-related neuropathology and improves cognitive impairment in APP/PS1 transgenic mice | |
Ge et al. | Down-expression of the NLRP3 inflammasome delays the progression of diabetic retinopathy | |
Chen et al. | Polysaccharide Krestin prevents Alzheimer’s Disease-type Pathology and Cognitive deficits by enhancing monocyte Amyloid-β Processing | |
JP2022027864A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases | |
JP6636614B2 (en) | Drug and therapeutic target screening method for treating Alzheimer's disease | |
Gao et al. | Acteoside ameliorates learning and memory impairment in APP/PS1 transgenic mice by increasing Aβ degradation and inhibiting tau hyperphosphorylation | |
CN114931591A (en) | Application of cotton rose hibiscus leaf extract in medicine for treating neurodegenerative diseases | |
KR20200116054A (en) | Composition for preventing or treating neuroinflammation diseases comprising bee venom extract | |
JP7249433B2 (en) | Composition for prevention or treatment of neuroinflammatory disease containing bee venom extract as an active ingredient | |
JP2011513440A (en) | Β-sheet destruction peptide for prevention and / or treatment of Alzheimer's disease | |
Yan et al. | Deoxyschizandrin attenuates Aβ1–42-induced cognitive impairments through up-regulation of AMPA receptors in mice | |
Hu et al. | A Novel scFv Anti-aβ Antibody Reduces Pathological Impairments in APP/PS1 Transgenic Mice via Modulation of Inflammatory Cytokines and Aβ-Related Enzymes | |
Patel et al. | Postinfectious epilepsy | |
KR102051758B1 (en) | Composition for treating or preventing dementia comprising 2-(3-[2-(1-Cyclohexen-1-yl)ethyl]-6,7-dimethoxy-4-oxo-3,4-dihydro-2- quinazolinylsulfanyl)-N-(4-ethylphenyl)butanamide as an active ingredient | |
JP7502882B2 (en) | Polyglutamine protein aggregation inhibitor and drug for preventing or treating polyglutamine disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220823 |